The safety of novel gut peptide ghrelin for the treatment of chronic kidney disease

The safety of novel gut peptide ghrelin for the treatment of chronic kidney disease - The safety ofghrelin

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011673

Enrollment

Registered

2013-09-10

Start date

2013-09-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease

Interventions

ghrelin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age over 20 years old 2. CKD patients at the stage, G3 and G4 3. BMI under 25 4. the patients that can cooperate with our study

Exclusion criteria

Exclusion criteria: 1. subjects with severe liver dysfunction 2. subjects with neoplasma 3. subjects with severe infection 4. subjects with psychogenic disorder 5. sujects with allergic reaction to wheat, egg, and milk 6. pregnant women 7. subjects tha were not egligble for the stusy

Design outcomes

Primary

Measure	Time frame
The temporal change of plasma concentration of ghrelin after the iv infusion	—

Secondary

Measure	Time frame
Change of eGFR Anthropodic change Renal function Metabolic marker Oxidative stressmarker Nutrition status Adverse effects by ghrelin infusion	—

Countries

Japan

Contacts

Public ContactShu Wakino

Keio University, Scool of Medicine Division of nephrology, endocrinology, and metabolism

shuwakino@z8.keio.jp03-3353-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026